JAK inhibitor has a bright market prospect in the treatment of rheumatoid arthritis
Analysts have pointed out that JAK inhibitor class will be the main driving force for the growth of rheumatoid arthritis drug market before 2022. This is mainly for patients requiring mono-therapy. These patients account for 30 % of all patients with rheumatoid arthritis.
In November 2012, the U.S. Food and Drug Administration (FDA) approvedtofacitinib, a JAK inhibitor developed by Pfizer, for treatment of rheumatoid arthritis. Data from a planned 12-month drug trial interim analysis shows that for patients receiving methotrexate therapy, tofacitinib can inhibit the progression of structural damage and improving disease activity in patients. Nevertheless, the drug has not yet been approved in Europe based on the concerns of safety and effectiveness of tofacitinib.
An oral JAK1 and JAK2 inhibitor, baricitinib, which is co-developed by Lilly and Incyte is currently in phase clinical trials. From the results of Phase clinical trial published in 2013 , we could see that the patients have a significant improvement of clinical symptoms after treated with the drug for 24 weeks and 52 weeks.
JAK3 inhibitor VX-509 is an investigational oral medicine beingdevelopedby Vertex. In the b clinical trials of VX-509, patients also achieved atleast a 20 percent improvement in signs and symptoms of rheumatoid arthritis. While the three highest dose groups showed ACR20 responses up to 68 percent.
In addition, JAK1 inhibitor GLPG0634 co-developed by Galapagos and Abbott life company is ongoing Phase clinical trials. JAK1 and JAK3 inhibitor ASTP15K developed by Astellas has entered phaseb clinical trials.
Interleukin inhibitors for treatment of rheumatoid arthritis
The new subcutaneous formulation of actemra-a humanized IL-6 receptor antagonist which is developed by Genetech-has received FDA approval in October, 2013 (previously approved by the administration of intravenous administration). Tocilizumab is used in adult rheumatoid arthritis patients who suffer Moderate to severe active rheumatoid arthritis and lack response to one or more anti-rheumatic drugs.
Regeneron and Sanofi company announced the phase clinical trial results of their co-developed IL-6 receptor inhibitor Sarilumab. 52 weeks trials of combination therapy with methotrexate showed that the drug may increase the patient’s body function as well as inhibit the progress of joint destruction, and thereby improving the effectiveness of methotrexate mono-therapy.
Also in October, 2013, Bristol-Myers Squibb announced the phase IIb clinical trial data of Clazakizumab, a humanized monoclonal antibody to IL-6. Research data indicated that the drug showed good results not only when combined with ethotrexate but also when used as mono-therapy.
Another IL-6 inhibitor co-developed by Yeung Sum and GlaxoSmithKline is in phase clinical trials which is expected to complete in 2016.
Ablynx Company possesses a Nanobodies ALX-0061 for IL-6 receptor. This drug is also in phase clinical trial. The early tests show ALX-0061 can alleviate symptoms of rheumatoid arthritis. Order Nutlin-3b kinase inhibitors
Novartis IL-17 inhibitor secukinumab (AIN457), in the study were found to have a role in the treatment of rheumatoid arthritis and psoriatic arthritis disease.
An IL-17 inhibitor (secukinumab, AIN457) developed by Novartis has been verified to have function in the treatment of rheumatoid arthritis and psoriatic arthritis disease.